Ann: MAYNE PHARMA provides FDA update on generic NUVARING, page-14

As far as Myring is concerned it is all lost.
Not 100% certain but believe it is exactly
12 months to the day. October 6 2020
when we received last CRL from FDA .
Richards response then was “In A TIMELY
MANNER” The same as 2019. Now they
will respond but not inform shareholders
when. Revenue for Nuvaring including Generic
mis now $670m . It has dropped by 1/3.
. obviously because generic suppliers are
continually dropping prices to gain market
share. It will be non profitable by the time
we get approval ( If Ever). These two Companies are both completely incompetent
regarding Generic fda approval. As stated
earlier they are probably trying to approve a
generic with shelf life and storage temperature
range superior to Nuvaring. FDA don’t like
generic manufacturing companies trying to
be slick. They should just copy exactly original
product. Mayne should just forget Myring
and invest $$$ and time in a profitable area
Richards and Fornieri ( Mithra largest shareholder are both a couple of fleas Richards
should just resign with his two mates.